Home › NDC Lookup › Ingredients › Azathioprine › 60219-1076-01
⚪image loading
(from DailyMed)

Azathioprine 50 mg Tablet, 100-count — NDC 60219-1076-1 (Billing 60219-1076-01)

by Amneal Pharmaceuticals NY LLC · 100 TABLET in 1 BOTTLE

This is a package of 100 tablets of Azathioprine 50 mg Tablet from Amneal Pharmaceuticals NY LLC, marketed since Feb 2015 and currently FDA-listed; retail pharmacies pay about $0.1243 per tablet (NADAC). It is this product's only package size.

NDC 60219-1076-01
🏷️ FDA NDC (as labeled) 60219-1076-1 billing pads the package segment with a zero
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 60219-1076-1 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
60219 labeler · 1076 product · 1 package
Package marketed since
Feb 2, 2015
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Billing quantity
100 EA per package
Barcode (UPC-A, from the NDC)
3 6021910761 8
Medicaid fills, this package
36,515 prescriptions in the last four reported quarters
FDA record last changed
Oct 8, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 60219-1076-1
Product NDC 60219-1076
11-digit billing NDC 60219107601
NCPDP billing unit EA — each (per item)
Application # ANDA074069
SPL Set ID 7e0d6d31-b15a-4671-8755-06b7746931db
Established class (EPC) Purine Antimetabolite
Mechanism of action Nucleic Acid Synthesis Inhibitors
Chemical class Nucleosides; Purines
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2015-02-02
Route ORAL
Dosage form TABLET
Substance AZATHIOPRINE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 011682
GCN 46771
HICL code 004523
Ingredient (HICL) Azathioprine
HIC1 code Z
Therapeutic class — broad (HIC1) Body As A Whole
HIC2 code Z2
Therapeutic class — intermediate (HIC2) Antihistamines, Antiserotonins, Immunosuppressants
HIC3 code Z2E
Therapeutic class — specific (HIC3) Immunosuppressives
AHFS code 90:28.08.92
AHFS class Antimetabolites, Immunosupp Therapy Misc
FDB label name AZATHIOPRINE 50 MG TABLET
FDB brand name Azathioprine
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 011682
  • GCN: 46771
  • HICL (First Databank): 004523
  • AHFS class code: 90:28.08.92
Why two NDCs? The FDA registers this code as 60219-1076-1 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 60219-1076-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name AZATHIOPRINE 50 MG TABLET Ingredient Azathioprine
📖 What it is MedlinePlus · NLM

Azathioprine is used with other medications to prevent transplant rejection (attack of the transplanted organ by the immune system) in people who received kidney transplants. It is also used to treat severe rheumatoid arthritis (a condition in which the body attacks its own joints, causing pain, swelling, and loss of function) when other medications and treatments have not helped. Azathioprine is in a class of medications called immunosuppressants. It works by decreasing the activity of the body's immune system so it will not attack the transplanted organ or the joints.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It helps prevent your body from rejecting a transplanted kidney, and it is also used to reduce the signs and symptoms of active rheumatoid arthritis. It works by calming down the i...
  • The tablets (Imuran, Azasan or generic azathioprine) are taken by mouth, usually once daily, though for rheumatoid arthritis the day's dose may be split in two. Follow your prescri...
  • It usually takes about 6 to 8 weeks, and your doctor will want to give it at least 12 weeks before deciding whether it is helping. Keep taking it as directed in the meantime.
  • How long before it works for my arthritis?
📖 Read our full Azathioprine guide →
1
Nutrient depletion considerations

Azathioprine may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Azathioprine nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.124 $12.43 / 100 tablets
Medicaid paysCMS SDUD · 12 mo $0.2848 $28.48 / 100 tablets
Medicare drug plans payPart D · Q2 2026 $0.3186 $31.86 / 100 tablets
Medicare Part B allowsASP · J7500 $0.136 / J7500 unit —
NADAC price history (per ea) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.244 $0.124
▼ Down 46% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Billing & reimbursement

FDA NDC (as labeled)60219-1076-1
11-digit billing NDC60219-1076-01
Format5-4-1 as registered → padded to 5-4-2 for billing (zero added to the package segment)
HCPCS J-codeJ7500
DescriptorAZATHIOPRINE, ORAL, 50 MG
Billing units / pkg1 units
How the units are derivedThis package is 100 EA; the HCPCS unit is 50 MG, so one package = 1 billing unit.
Medicare Part B spend (2026 (Q1))$20,737 · 6,362 claims · $3.26 per claim (all NDCs under J7500)
Crosswalk sourcePDAC NDC-HCPCS crosswalk (DME MAC / DMEPOS)
Where does this data come from?
The HCPCS J-code crosswalk comes from the CMS ASP NDC-HCPCS crosswalk and the DMEPDAC (DME MAC) NDC-HCPCS crosswalk — free public CMS data. Billing units are derived from the code’s descriptor and the package amount.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
60219-1076-01 You're viewing this Main listing 100 TABLET in 1 BOTTLE 2015-02-02 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Azathioprine 50 mg 16571-0835-01 Rising 100 tablets $0.124 AB Availability likely —
Azathioprine 50 mgthis 60219-1076-01 Amneal 100 tablets $0.124 AB Availability likely —
Azathioprine 50 mg 67877-0493-01 Ascend 100 tablets $0.124 AB Availability likely —
Azathioprine 50 mg 68084-0229-01 American 100 tablets $0.124 AB Availability likely —
Azathioprine 50 mg 68382-0003-01 Zydus 100 tablets $0.124 AB Availability likely —
Azathioprine 50 mg 68462-0502-01 Glenmark 100 tablets $0.124 AB Availability likely —
Imuran 50 mg 54766-0590-10 Sebela 100 tablets $8.891 AB Availability likely +7054%
Azathioprine 50 mg 42291-0071-01 AvKARE 100 tablets — AB FDA listed —
Azathioprine 50 mg 51407-0182-01 Golden 100 tablets — AB FDA listed —
Azathioprine 50 mg 65841-0602-01 Zydus 100 tablets — AB FDA listed —
Azathioprine 50 mg 68071-3772-06 NuCare 60 tablets — AB FDA listed —
Azathioprine 50 mg 68071-3997-06 NuCare 60 tablets — AB FDA listed —
Azathioprine 50 mg 69238-1076-01 Amneal 100 tablets — AB FDA listed —
Azathioprine 50 mg 70518-3544-00 REMEDYREPACK 100 tablets — AB FDA listed —
Azathioprine 50 mg 71610-0124-09 Aphena 9000 tablets — AB FDA listed —
Azathioprine 50 mg 72789-0129-30 PD-Rx 30 tablets — AB FDA listed —
Imuran 50 mg 83107-0025-10 Legacy 100 tablets — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2015
On the market since
Feb 2015
📍
2026
Currently FDA-listed
11 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Azathioprine inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerAmneal Pharmaceuticals NY LLC
Application holderAMNEAL PHARMACEUTICALS LLC
FDA applicationANDA074069 (ANDA)
Labeler code60219
First marketedFeb 2015
Product typeHuman Prescription Drug
Portfolio372 products on file

More NDCs from Amneal Pharmaceuticals NY LLC labeler code 60219

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
36.5K
Units reimbursed last 4 qtrs
2.8M
Gross reimbursed last 4 qtrs
$785.6K
Avg / prescription
$21.52
Avg / unit
$0.2848
Latest quarter Q1 2026
8.1KRx
Medicaid pays / ea
$0.2848
gross reimbursed
vs
NADAC / ea
$0.1243
acquisition cost
=
Spread
+$0.1605
+129% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
36% FFS 64% MCO
Fee-for-service · 13,010 Rx Managed care · 23,505 Rx
State Medicaid map
Alaska: 6,035 units · 823 per 100k residents AK Maine: 14,771 units · 1,059 per 100k residents ME Washington: 63,892 units · 818 per 100k residents WA Idaho: 21,153 units · 1,077 per 100k residents ID Montana: 9,916 units · 876 per 100k residents MT North Dakota: 2,286 units · 292 per 100k residents ND Minnesota: 53,120 units · 926 per 100k residents MN Wisconsin: 42,326 units · 716 per 100k residents WI Michigan: 82,027 units · 817 per 100k residents MI New York: 223,211 units · 1,141 per 100k residents NY Vermont: 3,341 units · 516 per 100k residents VT New Hampshire: 16,730 units · 1,193 per 100k residents NH Oregon: 77,117 units · 1,822 per 100k residents OR Nevada: 16,867 units · 528 per 100k residents NV Wyoming: no data reported WY South Dakota: 4,155 units · 452 per 100k residents SD Iowa: 16,010 units · 499 per 100k residents IA Illinois: 145,354 units · 1,158 per 100k residents IL Indiana: 112,893 units · 1,645 per 100k residents IN Ohio: 141,648 units · 1,202 per 100k residents OH Pennsylvania: 182,693 units · 1,410 per 100k residents PA New Jersey: 62,406 units · 672 per 100k residents NJ Massachusetts: 157,197 units · 2,245 per 100k residents MA California: 149,020 units · 382 per 100k residents CA Utah: 16,516 units · 483 per 100k residents UT Colorado: 50,632 units · 861 per 100k residents CO Nebraska: 12,923 units · 653 per 100k residents NE Missouri: 95,058 units · 1,534 per 100k residents MO Kentucky: 38,582 units · 852 per 100k residents KY West Virginia: 24,580 units · 1,389 per 100k residents WV Virginia: 173,308 units · 1,988 per 100k residents VA Maryland: 64,391 units · 1,042 per 100k residents MD Connecticut: 46,385 units · 1,282 per 100k residents CT Rhode Island: 26,526 units · 2,422 per 100k residents RI Arizona: 37,048 units · 499 per 100k residents AZ New Mexico: 28,226 units · 1,335 per 100k residents NM Kansas: 7,723 units · 263 per 100k residents KS Arkansas: 23,942 units · 781 per 100k residents AR Tennessee: 21,320 units · 299 per 100k residents TN North Carolina: 167,514 units · 1,546 per 100k residents NC South Carolina: 57,295 units · 1,066 per 100k residents SC Delaware: 954 units · 92.5 per 100k residents DE Oklahoma: 54,920 units · 1,355 per 100k residents OK Louisiana: 26,596 units · 581 per 100k residents LA Mississippi: 13,921 units · 474 per 100k residents MS Alabama: 34,184 units · 669 per 100k residents AL Georgia: 64,127 units · 581 per 100k residents GA D.C.: 13,284 units · 1,956 per 100k residents DC Hawaii: no data reported HI Texas: no data reported TX Florida: 45,815 units · 203 per 100k residents FL
Units reimbursed · per 100k residents
92.52,422
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Rhode Island 2,422 /100k
2 Massachusetts 2,245 /100k
3 Virginia 1,988 /100k
4 D.C. 1,956 /100k
5 Oregon 1,822 /100k
6 Indiana 1,645 /100k
7 North Carolina 1,546 /100k
8 Missouri 1,534 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Azathioprine — the program that covers self-administered drugs. 7 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Azathioprine. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$4.28M
Claims incl. refills
95.7K
Beneficiaries
67.2K
Spend / beneficiary
$63.69
Spend / claim
$44.68
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Azathioprine — the ingredient across all brands.

Top reported reactions

Condition Aggravated7,063
Arthralgia6,254
Diarrhoea5,684
Fatigue5,552
Nausea5,517
Headache4,768
Pain4,520

Age at onset

Neonate569
Infant95
Child543
Adolescent834
Adult11,072
Elderly2,435

Reporter sex

89,586 reports
Male · 38%
Female · 62%
Unknown · 0%

Serious outcomes

Hospitalization31,037
Death9,289
Life-threatening5,656
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 7,018 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
← 60219-1031-07 · Amneal 60219-1100-01 · Amneal →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.